Antidepressant fluoxetine alleviates colitis by reshaping intestinal microenvironment.
IBD
Intestinal microenvironment
Single cell sequencing
Journal
Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464
Informations de publication
Date de publication:
12 Mar 2024
12 Mar 2024
Historique:
received:
03
11
2023
accepted:
21
02
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
epublish
Résumé
The impact of antidepressants on Inflammatory bowel diseases (IBD) has been extensively studied. However, the biological effects and molecular mechanisms of antidepressants in alleviating colitis remain unclear. We systematically assessed how antidepressants (fluoxetine, fluvoxamine and venlafaxine) affected IBD and chose fluoxetine, the most effective one, for mechanism studies. We treated the C56BL/6 mice of the IBD model with fluoxetine and their controls. We initially assessed the severity of intestinal inflammation in mice by body weight loss, disease Activity Index scores and the length of the colon. The H&E staining and immunohistochemical staining of MUC2 of colon sections were performed to observe the pathological changes. RT-qPCR and western blot were conducted to assess the expression level of the barrier and inflammation-associated genes. Then, single-cell RNA sequencing was performed on mouse intestinal mucosa. Seurat was used to visualize the data. Uniform Manifold Approximation and Projection (UMAP) was used to perform the dimensionality reduction. Cell Chat package was used to perform cell-cell communication analysis. Monocle was used to conduct developmental pseudotime analysis. Last, RT-qPCR, western blot and immunofluorescence staining were conducted to test the phenomenon discovered by single-cell RNA sequencing in vitro. We found that fluoxetine treatment significantly alleviated colon inflammation. Notably, single-cell RNA sequencing analysis revealed that fluoxetine affected the distribution of different cell clusters, cell-cell communication and KEGG pathway enrichment. Under the treatment of fluoxetine, enterocytes, Goblet cells and stem cells became the dominating cells. The pseudotime analysis showed that there was a trend for M1 macrophages to differentiate into M2 macrophages. Lastly, we tested this phenomenon in vitro, which exhibited anti-inflammatory effects on enterocytes. Fluoxetine exhibited anti-inflammatory effects on intestinal mucosa via remodeling of the intestinal cells and macrophages, which reveals that fluoxetine is a promising therapeutic drug for the treatment of IBD and psychiatric comorbidities.
Sections du résumé
BACKGROUND
BACKGROUND
The impact of antidepressants on Inflammatory bowel diseases (IBD) has been extensively studied. However, the biological effects and molecular mechanisms of antidepressants in alleviating colitis remain unclear.
METHODS
METHODS
We systematically assessed how antidepressants (fluoxetine, fluvoxamine and venlafaxine) affected IBD and chose fluoxetine, the most effective one, for mechanism studies. We treated the C56BL/6 mice of the IBD model with fluoxetine and their controls. We initially assessed the severity of intestinal inflammation in mice by body weight loss, disease Activity Index scores and the length of the colon. The H&E staining and immunohistochemical staining of MUC2 of colon sections were performed to observe the pathological changes. RT-qPCR and western blot were conducted to assess the expression level of the barrier and inflammation-associated genes. Then, single-cell RNA sequencing was performed on mouse intestinal mucosa. Seurat was used to visualize the data. Uniform Manifold Approximation and Projection (UMAP) was used to perform the dimensionality reduction. Cell Chat package was used to perform cell-cell communication analysis. Monocle was used to conduct developmental pseudotime analysis. Last, RT-qPCR, western blot and immunofluorescence staining were conducted to test the phenomenon discovered by single-cell RNA sequencing in vitro.
RESULTS
RESULTS
We found that fluoxetine treatment significantly alleviated colon inflammation. Notably, single-cell RNA sequencing analysis revealed that fluoxetine affected the distribution of different cell clusters, cell-cell communication and KEGG pathway enrichment. Under the treatment of fluoxetine, enterocytes, Goblet cells and stem cells became the dominating cells. The pseudotime analysis showed that there was a trend for M1 macrophages to differentiate into M2 macrophages. Lastly, we tested this phenomenon in vitro, which exhibited anti-inflammatory effects on enterocytes.
CONCLUSIONS
CONCLUSIONS
Fluoxetine exhibited anti-inflammatory effects on intestinal mucosa via remodeling of the intestinal cells and macrophages, which reveals that fluoxetine is a promising therapeutic drug for the treatment of IBD and psychiatric comorbidities.
Identifiants
pubmed: 38475799
doi: 10.1186/s12964-024-01538-5
pii: 10.1186/s12964-024-01538-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
176Subventions
Organisme : Subject of National Key Research and Development Program
ID : 2022YFC3602104
Organisme : Special Scientific Research Fund for Tutor
ID : YYDSZX201901
Organisme : Beijing Science and Technology Program
ID : Z211100002921028
Organisme : Capital's Funds for Health Improvement and Research
ID : CFH2022-2-2025, 20200402085
Informations de copyright
© 2024. The Author(s).
Références
Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720–7. https://doi.org/10.1038/nrgastro.2015.150 .
doi: 10.1038/nrgastro.2015.150
Walker JR, Ediger JP, Graff LA, Greenfeld JM, Clara I, Lix L, et al. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol. 2008;103:1989–97. https://doi.org/10.1111/j.1572-0241.2008.01980.x .
doi: 10.1111/j.1572-0241.2008.01980.x
Panara AJ, Yarur AJ, Rieders B, Proksell S, Deshpande AR, Abreu MT, et al. The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study. Aliment Pharmacol Ther. 2014;39:802–10. https://doi.org/10.1111/apt.12669 .
doi: 10.1111/apt.12669
Regueiro M, Greer JB, Azigethy E. Etiology and treatment of pain and psychosocial issues in patients with inflammatory bowel diseases. Gastroenterology. 2017;152(2):430–9. https://doi.org/10.1053/j.gastro.2016.10.036 .
doi: 10.1053/j.gastro.2016.10.036
Barberio B, Zamani M, Black CJ, Savarino EV, Ford AC. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(5):359–370. DOI: https://doi.org/10.1016/S2468-1253(21)00014-5 .
Fairbrass KM , Lovatt J, Barberio B, Yuan Y, Gracie DJ, Ford AC . Bidirectional brain-gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis. Gut.2021. DOI: https://doi.org/10.1136/gutjnl-2021-325985
Alexakis C, Kumar S, Saxena S, Pollok R. Systematic review with meta-analysis: the impact of a depressive state on disease course in adult inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46:225–35. https://doi.org/10.1111/apt.14171 .
doi: 10.1111/apt.14171
Persoons P, Vermeire S, Demyttenaere K, Fischler B, Vandenberghe J, Van Oudenhove L. The impact of major depressive disorder on the short- and long-term outcome of Crohn’s disease treatment with infliximab. Aliment Pharmacol Ther. 2005;22:101–10. https://doi.org/10.1111/j.1365-2036.2005.02535.x .
doi: 10.1111/j.1365-2036.2005.02535.x
Frolkis AD, Vallerand IA, Shaheen AA, Lowerison MW, Swain MG, Barnabe C. Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression. Gut. 2019;68:1606–12. https://doi.org/10.1136/gutjnl-2018-317182 .
doi: 10.1136/gutjnl-2018-317182
Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry. 1999;60(Suppl 4):4–11. discussion 12–3.
Hatamnejad MR, Ghavami SB, Shirvani M, Ahmadabad MA, Shahrokh S, Farmani M, et al.Selective serotonin reuptake inhibitors and inflammatory bowel disease; Beneficial or malpractice.Front Immunol. 2022:13:980189.
Tynan RJ, Weidenhofer, J, Hinwood M, Cairns MJ, Day TA, Walker FR. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun. 2012;26(3):469–79.
doi: 10.1016/j.bbi.2011.12.011
Sales MC, Kasahara TM, Sacramento PM, Rossi AD, Cafasso MO, Oyamada HAA. Selective serotonin reuptake inhibitor attenuates the hyperresponsiveness of TLR2+ and TLR4+ Th17/Tc17-like cells in multiple sclerosis patients with major depression. Immunology. 2021;162(3):290–305.
doi: 10.1111/imm.13281
Zhu J, Smith K, Hsieh PN, Mburu YK, Chattopadhyay S, Sen GC, et al. High-throughput screening for TLR3-IFN regulatory factor 3 signaling pathway modulators identifies several antipsychotic drugs as TLR inhibitors. J Immunol. 2010;184(10):5768–76.
doi: 10.4049/jimmunol.0903559
Liu YJ, Tang B, Wang FC, Tang L, Lei YY, Luo Y, et al. Parthenolide ameliorates colon inflammation through regulating Treg/Th17 balance in a gut microbiota-dependent manner. Theranostics. 2020;10(12):5225–41. https://doi.org/10.7150/thno.43716 .
doi: 10.7150/thno.43716
pmcid: 7196297
Ke Wu, Liu Y-Y, Shao S, Song W, Chen X-H, Dong Y-T, et al. The microglial innate immune receptors TREM-1 and TREM-2 in the anterior cingulate cortex (ACC) drive visceral hypersensitivity and depressive-like behaviors following DSS-induced colitis. Brain Behav Immun. 2023;112:96–117. https://doi.org/10.1016/j.bbi.2023.06.003 .
doi: 10.1016/j.bbi.2023.06.003
Mikocka-Walus A, Ford AC, Drossman DA. Antidepressants in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(3):184–92. https://doi.org/10.1038/s41575-019-0259-y .
doi: 10.1038/s41575-019-0259-y
Vicentini FA, Szamosi JC, Rossi L, Griffin L, Nieves K, Bihan D, et al. Colitis-associated microbiota drives changes in behaviour in male mice in the absence of inflammation. Brain Behav Immun. 2022May;102:266–78. https://doi.org/10.1016/j.bbi.2022.03.001 .
doi: 10.1016/j.bbi.2022.03.001
Shiyan Yu, Balasubramanian I, Laubitz D, Tong K, Bandyopadhyay S, Lin X, et al. Paneth Cell-Derived Lysozyme Defines the Composition of Mucolytic Microbiota and the Inflammatory Tone of the Intestine. Immunity. 2020;53(2):398-416.e8. https://doi.org/10.1016/j.immuni.2020.07.010 .
doi: 10.1016/j.immuni.2020.07.010
Ghia JE, Blennerhassett P, Collins SM. Impaired parasympathetic function increases susceptibility to inflammatory bowel disease in a mouse model of depression. Clin Invest. 2008;118:2209–18. https://doi.org/10.1172/JCI32849 .
doi: 10.1172/JCI32849
Ghia JE, Blennerhassett P, Deng Y, Verdu EF, Khan WI, Collins SM. Reactivation of inflammatory bowel disease in a mouse model of depression. Gastroenterology. 2009;136(7):2280–8. https://doi.org/10.1053/j.gastro.2009.02.069 .
doi: 10.1053/j.gastro.2009.02.069
Coleman JA, Green EM, Gouaux E. X-ray structures and mechanism of the human serotonin transporter. Nature. 2016;532(7599):334–33. https://doi.org/10.1038/nature17629 .
doi: 10.1038/nature17629
pmcid: 4898786
Karmakar S, Lal G. Role of serotonin receptor signaling in cancer cells and anti-tumor immunity. Theranostics. 2021;11(11):5296–312. https://doi.org/10.7150/thno.55986 .
doi: 10.7150/thno.55986
pmcid: 8039959
Nieto C, Rayo I, de Las Casas-Engel M, Izquierdo E, Alonso B, Béchade C, et al. Serotonin (5-HT) Shapes the Macrophage Gene Profile through the 5-HT(2B)-Dependent Activation of the Aryl Hydrocarbon Receptor. J Immunol. 2020;204:2808–17. https://doi.org/10.4049/jimmunol.1901531 .
doi: 10.4049/jimmunol.1901531
Spohn SN, Bianco F, Scott RB, Keenan CM, Linton AA, O’Neill CH, et al. Protective Actions of Epithelial 5-Hydroxytryptamine 4 Receptors in Normal and Inflamed Colon. Gastroenterology. 2016;151(5):933-944.e3. https://doi.org/10.1053/j.gastro.2016.07.032 .
doi: 10.1053/j.gastro.2016.07.032
Daghaghzadeh H, Naji Fa, Afshar H, Sharbafchi MR, Feizi A, Maroufi M. Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: a double-blind controlled study. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2015;20(6):595–601.
doi: 10.4103/1735-1995.165969
Yanartas O, Kani HT, Bicakci E, Kilic I, Banzragch M, Acikel C, et al. The effects of psychiatric treatment on depression, anxiety, quality of life, and sexual dysfunction in patients with inflammatory bowel disease. Neuropsychiatr Dis Treat. 2016;12:673–83.
doi: 10.2147/NDT.S106039
pmcid: 4818049
Macer BJ, Prady SL, Mikocka-Walus A. Antidepressants in Inflammatory Bowel Disease: A Systematic Review. Inflamm Bowel Dis. 2017;23(4):534–50.
doi: 10.1097/MIB.0000000000001059